


ONLINE APPENDIX:**Utility of adding information on working hours to the prediction of coronary heart disease: the Whitehall study**

Mika Kivimäki, G. David Batty, Mark Hamer, Jane E. Ferrie, Jussi Vahtera, Marianna Virtanen, Michael G. Marmot, Archana Singh-Manoux and Martin J. Shipley



eFigure 1. Flow-diagram of the sample selection

eTable 1. Comparison between included and excluded participants free of prevalent coronary heart disease at study baseline.

Characteristic*	Included		Excluded		P-value
	N	M±SD/%	N	M± SD/%	
Age, y	7095	48.8±5.7	1437	53.6±6.3	<0.001
Sex, %					<0.001
Male	4986	70.3	864	60.1	
Female	2109	29.7	573	39.9	
Ethnic group, %					<0.001
White	6465	91.1	1253	87.2	
Non-white	630	8.9	184	12.8	
Incident coronary heart disease at follow-up					0.177
None	6903	97.3	1384*	96.5	
Non-fatal myocardial infarction	163	2.3	40	2.8	
Coronary death	29	0.4	10	0.7	

* 3 Participants excluded because of loss to follow-up

eTable2. Crude coronary heart disease event rates by categories of 10-year predicted risk calculated using the Framingham risk score alone and in combination with information on long working hours.

10-year predicted risk category, %	Person-years	N of participants	N of events	Rate*	Rate ratio
Framingham alone					
<5.0	74,695.9	6554	150	2.0	1.00
5.0 – 9.9	4,696.5	436	34	7.2	3.61 (2.48 to 5.23)
≥10.0	1,018.6	105	8	7.9	3.91 (1.92 to 7.96)
Framingham and working hours					
<5.0	74,125.7	6498	143	1.9	1.00
5.0 – 9.9	5,228.0	489	38	7.3	3.77 (2.63 to 5.39)
≥10.0	1,057.1	108	11	10.4	5.39 (2.92 to 9.96)

*Rate per 1,000 person years

eTable3. Reclassification of the predicted 10-year risk of incident coronary heart disease for a risk score based on both the Framingham risk score and long working hours compared to the Framingham risk score alone among subgroups of the Whitehall participants.

Subgroup		N	Reclassified		Net correctly reclassified (%)
			Increased risk	Decreased risk	
Excluding non - white	CHD-case	159	11	3	5.0%
	Non-case	6306	125	90	-0.6%
	NRI (95%CI)				4.5% (-0.2 to 9.1)
	P-value				p=0.058
Excluding those on medication*	CHD-case	163	12	4	4.9%
	Non-case	6495	118	84	-0.5%
	NRI (95%CI)				4.4% (-0.4 to 9.2)
	P-value				p=0.075
Non-diabetics	CHD-case	180	13	4	5.0%
	Non-case	6716	126	95	-0.5%
	NRI (95%CI)				4.5% (0.0 to 9.0)
	P-value				p=0.049

*Antihypertensive medication (n=394), lipid-lowering drugs (n=43) and anti-platelet agents (n=17).